Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2023

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE GLOBAL MULTI-CENTER PHASE III CLINICAL TRIAL OF OT-101

Next Day Disclosure Return

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2023

VOLUNTARY ANNOUNCEMENT INCLUSION OF OT-1001 IN THE PRIORITY REVIEW AND APPROVAL PROCESS OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

2022 Annual Report

2022 Environmental, Social and Governance Report

NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 16, 2023

NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS

NOTICE OF ANNUAL GENERAL MEETING

VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR OT-1001 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2023

PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE SIXTH MEMORANDUM AND ARTICLES OF ASSOCIATION

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022

TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE

DATE OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-702 IN CHINA

VOLUNTARY ANNOUNCEMENT INITIATION OF THE PHASE II CLINICAL TRIAL OF OT-202

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2023

POSITIVE PROFIT ALERT

VOLUNTARY ANNOUNCEMENT COMPLETION OF THE PHASE I CLINICAL TRIAL OF OT-202

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2023

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-101 IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2022